Title: Expression System
Patent Number: 8,415,148
Filed: Aug. 2, 2011
Inventor: Jacques Perrault, San Diego State University
The invention, the patent’s abstract state, relates “generally to methods and compositions for expression of polypeptides or delivery of interfering RNAs in various cell types.”
Title: Devices, Systems, and Methods for Improving Memory and/or Cognitive Function through Brain Delivery of siRNA
Patent Number: 8,415,319
Filed: Sept. 23, 2011
Inventor: William Kaemmerer, Medtronic
The invention relates to “devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA,” according to the patent’s abstract. “Such compositions can be administered using devices, systems, and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The … invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.”
Title: Delivery of dsRNA to Arthropods
Patent Number: 8,415,320
Filed: July 10, 2012
Lead Inventor: Steven Whyard, Commonwealth Scientific and Industrial Research Organization
The invention relates to “methods of gene silencing in arthropods using dsRNA,” the patent’s abstract states. “The method [includes] contacting the arthropod with, and/or directly feeding the arthropod the dsRNA … to deliver the dsRNA to arthropod tissues. It is envisaged that the methods of the invention will have use in determining the biological function of genes in arthropods. Methods of pest control of arthropods and of protecting arthropods against parasites and predators are provided. Transgenic arthropods expressing dsRNA molecules are also provided.”
Title: microRNAs for Inhibiting Viral Replication
Patent Number: 8,415,323
Filed: Aug. 27, 2008
Inventor: Michael David, University of California, Oakland
The invention relates to “reducing accumulation of viral genomes in a target cell,” the patent’s abstract states. “In particular, the … invention provides compositions and methods for combating viral infection through RNA interference. Specifically, the … invention provides cellular microRNA mimics for treating virus-infected subjects.”
Title: Duplex Oligonucleotides with Enhanced Functionality in Gene Regulation
Patent Number: 8,415,466
Filed: April 30, 2012
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
The patent, its abstract states, claims “methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics [that] contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.”
Title: Down-Regulation of Gene Expression using Artificial microRNAs
Patent Number: 8,415,526
Filed: Jan. 11, 2012
Inventor: Brian McGonigle, DuPont
The invention, the patent’s abstract states, relates to “isolated nucleic acid fragments comprising precursor miRNA, and artificial miRNAs and their use in down-regulating gene expression.”
Title: Methylated Coding and Non-Coding RNA Genes as Diagnostic and Therapeutic Tools for Human Melanoma
Application Number: 20130084328
Filed: April 26, 2012
Inventor: Ranjan Perera, Sanford-Burnham Medical Research Institute
The patent application, its abstract states, claims “methods for the diagnosis and treatment of human melanoma and prediction of early disease genesis to metastasis by assessing CpG island methylation or expression level of epigenetically regulated differentially expressed coding or non-coding genes. Methods of treatment of human melanoma by modifying or regulating the same pathways are also provided.”
Title: Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1-Expression Neuroendocrine Tumors
Application Number: 20130084331
Filed: Dec. 4, 2012
Lead Inventor: John Nemunaitis, Gradalis
The invention comprises a “bi-functional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells,” the patent application’s abstract states. “The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.”
Title: Modified Nucleosides, Analogs Thereof, and Oligomeric Compounds Prepared Therefrom
Application Number: 20130084576
Filed: April 26, 2011
Lead Inventor: Thazha Prakash, Isis Pharmaceuticals
The invention comprises “modified nucleosides, analogs thereof, and oligomeric compounds prepared therefrom,” the patent application’s abstract states. “More particularly, the … invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double-stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.”
Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Prostate-Related Disorders
Application Number: 20130085077
Filed: Sept. 19, 2012
Lead Inventor: Carlo Croce, Ohio State University
The invention relates to “methods and compositions for the diagnosis, prognosis, and/or treatment of prostate associated disorders,” the patent application’s abstract states.